Eucardia intends to address one of the most growing disease that is already a major public health issue: Heart failure (HF).
Heart failure is a chronic, progressive condition that prevents the heart from pumping enough blood to meet the body’s needs. In EU and US HF affects about 15 million people, with an expected growth of about 38% by 2030. Two million of these patients are affected by advanced systolic heart failure (SHF): a phase in which the pharmacological therapies alone are no longer sufficient to manage the symptoms
Needless to say, HF has a significant social cost: i.e. the US costs related to the loss of work and household productivity are estimated at $ 8.2 billion / year (by 2030, $ 12.3 billion / year).
It is important to know that the actual wide diffusion and rising of HF is due to the combined effect of the aging of the population and the strong improvement of infarction treatments. In fact, by mitigating the short-term damages of ischemic events and improving survival, the number of patients which lately develop HF today is increasing. In addition, HF has no actual cure apart from heart transplantation, which is very rare (<10,000 patients / year / world) and not allowed to people over 65 (80% of HF patients).
Currently available treatments have staggering healthcare cost ($ 108 billion a year in the world; by 2030, $ 150 billion/year) and depend on the type and severity of the condition.
Eucardia is bringing to market a breakthrough implantable cardiac device: the Heart Damper (HD), which is intended to provide a simple, personalized, quick and cost-effective solution to treat patients affected by SHF, irrespective of their age. The HD is designed to be stably fitted into the left ventricle by a simple transapical surgical procedure, and to provide an increase in the ejection fraction and cardiac efficiency. Once in place, the device does not require any external power source.
Eucardia’s mission is to develop and industrialize the Heart Damper, ultimately giving SHF patients a longer and better life expectancy, while tackling the healthcare costs associated with medical treatments. In order to do that, the Company’s objective is to validate its technology in order to sign licensing agreements with MedTech industries to commercialise the product, according to a B2B business model.
